Ischemic stroke
Conditions
Interventions
Control Group:Conventional Western medical treatment for ischemic stroke includes antiplatelet aggregation, anticoagulation, lipid regulation and plaque stabilization, neuroprotection, etc.
for patients with other non-severe underlying diseases, routine symptomatic treatment is provided.
Treatment group:In addition to the conventional Western medicine treatment, the Qingre Kaiqiao decoction was administered at a dose of 1 per day, boiled in 200ml of water, and taken in two divided dos
Sponsors
Beijing University of Chinese Medicine Oriental Hospital
Eligibility
Sex/Gender
All
Age
41 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Meets the diagnostic criteria for acute ischemic stroke; (2) Meets the diagnostic criteria for stroke disease with exuberant heat inside and phlegm and blood stasis obstructing the meridians; (3) Age 41 to 80 years, both male and female; (4) First onset; (5) Time since onset =72 hours; (6) NIHSS score: 2 = score =15; (7) Informed and signed the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Intracranial space-occupying lesions, TIA, cerebral hemorrhage, subarachnoid hemorrhage, and other cerebrovascular diseases; (2) Post-stroke mental status disorders, such as somnolence, coma, or severe aphasia, making it impossible to answer questions or follow instructions independently; (3) Treatment with traditional Chinese medicine formulations such as Xuesaitong, Xingnaojing, and Danshen injection; (4) Preparation for or having undergone thrombolysis or mechanical thrombectomy; (5) Presence of gastrointestinal organic lesions, such as gastrointestinal bleeding or ulcers, or a tendency to bleed; (6) Concurrent severe primary diseases, such as hepatic or renal insufficiency, cardiopulmonary failure, or hematological disorders; (7) Presence of mental disorders that prevent cooperation with the trial; (8) History of suspected or confirmed drug or alcohol abuse; (9) Pregnant or breastfeeding women, or those with plans for pregnancy in the near future; (10) Allergy to this drug or a history of allergic constitution; (11) Poor compliance, inability to take medication on time, or participation in other drug clinical trials within the past month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Parabacteroides;Short-Chain Fatty Acids;D-lactic acid;Trimethylamine N-oxide;Total Cholesterol;Triglyceride;Interleukin-6;Interleukin-1ß;Interleukin-8;Interleukin-10;Tumor Necrosis Factor-alpha;High-sensitivity C-reactive protein;Neurological Deficit Score (NIHSS);TCM syndrome score;Alcaligenes;Enterobacter; | — |
Secondary
| Measure | Time frame |
|---|---|
| Modified Rankin Scale (mRS scoring);Activities of Daily Living (ADL) Assessment;Activities of Daily Living (ADL) Barthel Index; | — |
Countries
China
Contacts
Public ContactLiu Xue Mei
Beijing University of Chinese Medicine Oriental Hospital
Outcome results
None listed